<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="./datadict_v2.xsl"?><data_table id="pht002823.v2" study_id="phs000504.v2" participant_set="2" date_created="Wed Nov 27 13:25:49 2013"><variable id="phv00171450.v2"><name>SAMPID</name><description>De-identified Sample ID</description><type>string</type></variable><variable id="phv00171451.v2"><name>Sample Type</name><description>Indicates the Tumor / Normal status of a sample</description><type>string</type></variable><variable id="phv00171452.v2"><name>Tissue Site</name><description>General body site where sample was collected</description><type>string</type></variable><variable id="phv00171455.v2"><name>ANALYTE_TYPE</name><description>Molecular analyte</description><type>string</type></variable><variable id="phv00196127.v1"><name>Cho et al.</name><description>Six molecular subgroups of medulloblastoma (termed c1 to c6), each with a unique combination of numerical and structural chromosomal aberrations that globally influence mRNA and miRNA expression. For details see: Cho et al., 2011, &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/21098324"&gt;PMID:21098324&lt;/a&gt;</description><type>string</type></variable><variable id="phv00196128.v1"><name>Northcott et al.</name><description>Four distinct, nonoverlapping molecular variants (WNT, SHH, group C, and group D) with significant subgroup-specific demographics, histology, metastatic status, and DNA copy number aberrations. For details see: Northcott et al., 2011 &lt;a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20823417"&gt;PMID:20823417&lt;/a&gt;</description><type>string</type></variable><variable id="phv00196129.v1"><name>Histological Subtype</name><description>Subtype of medulloblastoma as determined by pathology review</description><type>string</type></variable></data_table>
